Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA 3745

Next Previous
Drug Profile

mRNA 3745

Alternative Names: mRNA-3745

Latest Information Update: 29 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics
  • Class RNA
  • Mechanism of Action Glucose 6 phosphatase expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type I
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glycogen storage disease type I

Most Recent Events

  • 28 Feb 2024 mRNA 3745 receives Orphan Drug status for Glycogen storage disease type I in European Union prior to February 2024
  • 09 Sep 2021 mRNA 3745 receives Orphan Drug status for Glycogen storage disease type I in USA
  • 09 Sep 2021 US FDA completes its review of the IND application mRNA 3745 allowing it to proceed to clinic for Glycogen storage disease type 1
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top